🇺🇸 FDA
Patent

US 8598149

Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

granted A61KA61K31/56A61K31/567

Quick answer

US patent 8598149 (Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists) held by Corcept Therapeutics Incorporated expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/56, A61K31/567, A61K31/575, A61P